Helix Historical Income Statement
| HBP Stock | CAD 1.00 0.05 5.26% |
Historical analysis of Helix BioPharma income statement accounts such as Selling General Administrative of 2.8 M or Total Revenue of 0.0 can show how well Helix BioPharma Corp performed in making a profits. Evaluating Helix BioPharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Helix BioPharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Helix BioPharma Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Helix BioPharma Corp is a good buy for the upcoming year.
Helix |
About Helix Income Statement Analysis
Helix BioPharma Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Helix BioPharma shareholders. The income statement also shows Helix investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Helix BioPharma Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Helix BioPharma Corp. It is also known as Helix BioPharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Helix BioPharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Helix BioPharma Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helix BioPharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Helix BioPharma's Discontinued Operations is very stable compared to the past year. As of the 4th of December 2024, Interest Income is likely to grow to about 37 K, while Depreciation And Amortization is likely to drop about 13.3 K.
| 2023 | 2024 (projected) | Minority Interest | 117K | 111.2K | Reconciled Depreciation | 14K | 13.3K |
Helix BioPharma income statement Correlations
Click cells to compare fundamentals
Helix BioPharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Helix BioPharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 212K | 173K | 12K | 13K | 14K | 13.3K | |
| Selling General Administrative | 2.7M | 3.2M | 595K | 299K | 3.3M | 2.8M | |
| Gross Profit | (212K) | (173K) | (12K) | (13K) | (14K) | (13.3K) | |
| Other Operating Expenses | 8.6M | 9.1M | 6.0M | 6.3M | 9.4M | 8.6M | |
| Operating Income | (8.6M) | (9.6M) | (6.5M) | (6.3M) | (9.4M) | (9.8M) | |
| Ebit | (8.7M) | (9.6M) | (6.0M) | (6.3M) | (9.4M) | (9.9M) | |
| Research Development | 5.9M | 5.9M | 4.5M | 5.3M | 6.1M | 5.0M | |
| Ebitda | (8.4M) | (9.5M) | (6.0M) | (6.3M) | (9.4M) | (9.8M) | |
| Cost Of Revenue | 212K | 173K | 12K | 13K | 14K | 13.3K | |
| Total Operating Expenses | 8.6M | 9.1M | 6.0M | 6.3M | 9.4M | 8.2M | |
| Income Before Tax | (8.6M) | (9.6M) | (6.6M) | (6.3M) | (9.4M) | (9.9M) | |
| Total Other Income Expense Net | 55K | (443K) | (523K) | 36K | (25K) | (26.3K) | |
| Net Income | (9.0M) | (7.9M) | (6.1M) | (6.3M) | (9.3M) | (9.7M) | |
| Income Tax Expense | 1K | 449K | (1.7M) | (484K) | (132K) | (138.6K) | |
| Net Income From Continuing Ops | (8.6M) | (9.6M) | (6.6M) | (6.3M) | (9.3M) | (9.7M) | |
| Net Income Applicable To Common Shares | (9.0M) | (8.0M) | (6.6M) | (6.3M) | (7.2M) | (7.6M) | |
| Interest Income | 55K | 37K | 23K | 31K | 35.7K | 37.0K | |
| Net Interest Income | 32K | (353K) | (14K) | 33K | 24K | 25.2K | |
| Reconciled Depreciation | 211K | 199K | 12K | 13K | 14K | 13.3K |
Pair Trading with Helix BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Helix BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Helix BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Helix Stock
| 0.83 | GOOG | Alphabet CDR | PairCorr |
| 0.79 | AMZN | Amazon CDR | PairCorr |
| 0.79 | NVDA | NVIDIA CDR | PairCorr |
| 0.79 | BOFA | Bank of America | PairCorr |
| 0.78 | JPM | JPMorgan Chase | PairCorr |
The ability to find closely correlated positions to Helix BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Helix BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Helix BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Helix BioPharma Corp to buy it.
The correlation of Helix BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Helix BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Helix BioPharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Helix BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Helix Stock
Helix BioPharma Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Helix BioPharma shareholders. The income statement also shows Helix investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).